TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

The USPTO issued TuHURA Biosciences Patent No. 12,760,104, extending claims for its VISTA-inhibiting antibody TBS-2025 to antibody modifications and bispecific/multispecific antibodies, combination uses, and potential applications beyond cancer, including autoimmune disease and infection. The patent term runs through February 18, 2042, before any potential extension; the company says the broader protection could support its VISTA franchise and future collaborations. TBS-2025 is in a Phase 1b trial, and the release provides no clinical results or market reaction.

Analysis

The patent adds defensive and partnering optionality to HURA’s VISTA program, but it does not de-risk the value-driving uncertainties: clinical activity, safety, development execution, and whether the claims withstand challenge. Broad coverage across antibody formats and indications matters only if HURA can develop or license those applications; patent breadth is not evidence of efficacy, freedom to operate, or exclusivity over every VISTA approach. The near-term effect is therefore sentiment and negotiating leverage, not a measurable revenue or valuation inflection.

The key distinction is that TBS-2025 is early-stage, while the company’s Phase 3 program is a separate asset. Do not conflate this patent with validation of the Phase 3 program or assume it changes the economics of the pembrolizumab combination. MRK has no evident direct read-through from the announcement; any benefit would require successful development of a combination, with no economics disclosed.

Over 1–3 months, watch for trial updates, licensing evidence, and the patent’s actual claim language and prosecution record. Over 6–18 months, clinical data and credible partner interest—not the patent announcement—would determine whether this becomes franchise value. Main downside risks are weak or toxic clinical results, slower enrollment, competing approaches, and narrower enforceable claims than the release implies. Contrarian view: the market may overvalue the headline breadth; equally, if investors treat the patent as routine paperwork, it may underrecognize its incremental option value for future deal discussions.

Key Decisions for Investors

• Do not chase HURA solely on the patent announcement; treat it as a modest positive to strategic optionality, not a change in clinical probability of success.
• For event-driven exposure, consider only a small, risk-capped HURA position after checking liquidity, cash runway, and the full patent claims. Reassess on TBS-2025 safety/activity data or a verifiable collaboration; no such catalyst timing is provided here.
• Monitor USPTO claim scope, prosecution history, and any challenges or competing VISTA patents. Narrower-than-announced claims or adverse validity developments would weaken the partnering thesis.
• Keep MRK neutral on this news: the release provides no evidence of a commercial arrangement or material change to pembrolizumab economics. Revisit only if a disclosed agreement or combination data establishes a direct link.